Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 457 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: SBRT Clear all

Conditions: Prostate Cancer, Cancer of the Prostate
Interventions: Ethos Varian treatment system, Adaptive stereotactic body radiotherapy, Androgen deprivation therapy; Device · Radiation · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prostate Cancer
Interventions: Stereotactic Body Radiation Therapy (SBRT) radiation for prostate cancer utilizing the Elekta Versa or Agility System.; Radiation
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Irvine, California

Conditions: Pancreatic Cancer Non-resectable
Interventions: Folfirinox, Stereotactic Body Radiation Therapy; Drug · Radiation
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Endometrial Cancer, Cervical Cancer
Interventions: External beam Radiotherapy; Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Any Solid Malignancies of Any Tissue Origin (Except for Small Cell Lung Cancer) Involving the Upper Abdomen and Thorax
Interventions: ETHOS, CT-guided stereotactic adaptive radiotherapy; Device · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prostate Cancer
Interventions: SBRT to whole prostate, IMRT followed by mpMRI guided SBRT boost with SIB to intraprostatic lesions; Radiation
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostatic Neoplasms, Prostate Cancer
Interventions: CDX1127, SBRT; Biological · Radiation
Lead sponsor: James Larner, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Hepatocellular Carcinoma
Interventions: SBRT, TACE; Radiation · Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer
Interventions: SBRT; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 19
States / cities: Birmingham, Alabama • Berkeley, California • Carmichael, California + 16 more

Conditions: Pancreatic Cancer
Interventions: Gemcitabine, Capecitabine, Stereotactic Body Radiation Therapy (SBRT); Drug · Radiation
Lead sponsor: David A. Clump, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive, Oropharyngeal Squamous Cell Carcinoma, p16 Positive Neoplastic Cells Present, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions: Durvalumab, Modified Radical Neck Dissection, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy, Transoral Robotic Surgery, Tremelimumab; Biological · Procedure · Other + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non Small Cell Lung Cancer
Interventions: Stereotactic radiation therapy, Durvalumab; Radiation · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cancer, Metastasis, Metastatic Cancer, Brain Metastases, Brain Metastases, Adult
Interventions: Azeliragon, Stereotactic radiosurgery, Corticosteroid; Drug · Radiation
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Recurrent Prostate Cancer, Prostate Cancer
Interventions: N-803, ETBX-71 Vaccine, 18F-DCFPyL; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pancreatic Cancer
Interventions: mFOLFIRINOX, Stereotactic body radiotherapy (SBRT); Drug · Radiation
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Lung Cancer Stage II, Lung Cancer Stage III, Non Small Cell Lung Cancer
Interventions: SBRT, Carboplatin, Paclitaxel, cis Platinum, Etoposide, IMRT, Durvalumab; Radiation · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Brain Metastases, Generalized Malignancy, Primary, Brain Lesions
Interventions: TPI 287, Fractionated Stereotactic Radiotherapy (FSRT); Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Lung Neoplasm
Interventions: Stereotactic Radiotherapy, Anatomic Pulmonary Resection; Radiation · Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2034
U.S. locations: 17
States / cities: Long Beach, California • West Los Angeles, California • Bay Pines, Florida + 14 more

Conditions: Hepatocellular Carcinoma
Interventions: TACE transarterial chemoembolization, stereotatic body radiotherapy (SBRT); Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 3
States / cities: Maywood, Illinois • Portland, Oregon • Philadelphia, Pennsylvania

Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions: hypofractionated radiation therapy, laboratory biomarker analysis, image-guided radiation therapy, carboplatin, paclitaxel, stereotactic body radiation therapy; Radiation · Other · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Metastatic Cancer
Interventions: surgical procedure, radiation therapy, stereotactic radiosurgery; Procedure · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Oligometastatic Prostate Cancer
Interventions: Quemliclustat, Etrumadenant, Zimberelimab, Stereotactic Body Radiation Therapy; Drug · Radiation
Lead sponsor: Catherine Spina; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Adenocarcinoma
Interventions: Leuprolide Acetate, Goserelin Acetate, Stereotactic Body Radiation Therapy, Radium Ra 223 Dichloride, Laboratory Biomarker Analysis, Degarelix; Drug · Radiation · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8, Recurrent Pancreatic Adenocarcinoma, Oligometastatic Pancreatic Ductal Adenocarcinoma
Interventions: Chemotherapy, Stereotactic Body Radiation Therapy, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Questionnaire Administration; Drug · Radiation · Procedure + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Search by objective public record fields.

Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer

Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer

Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers

Novel Optical Surface Image Guidance System for Beam-Gated Online Adaptive SBRT Delivery in Mobile Lower Lung and Upper Abdominal Malignancies

MRI Guided SBRT for Localized Prostate Cancer

Pilot Study of SBRT and CDX-1127 in Prostate Cancer

Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma

Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery

Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy

Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases

Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients

Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Radiation Therapy Following Surgery to Remove Brain Metastases

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer